
    
      This is a single-center, open-label study of daily human growth hormone (Genotropin®, 5.0
      μg/kg via subcutaneous injection) and testosterone (testosterone enanthate, 140mg via
      intramuscular injection every two weeks) for 24 weeks in men with FSHD with a 12 week washout
      period. A total of 20 subjects will be enrolled at the University of Rochester Medical Center
      in Rochester, NY.
    
  